Ranbaxy launches bio-generic product for osteoporosis patients

April 3rd, 2008 - 3:18 pm ICT by admin  

Mumbai, April 3 (IANS) Ranbaxy Thursday said it launched the world’s first bio-generic product Bonista-Teriparatide injection for the treatment of osteoporosis, a disease that leads to an increased risk of bone fracture. The product was indigenously researched at Virchow Biotech and developed with aid from the Department of Science and Technology.

Commenting on the launch of the product, Sanjeev I. Dani, senior vice president and regional director (Asia & CIS), Ranbaxy, said: “The osteoporosis segment in India currently has a market size of around Rs.2.19 billion and grew more than two percent in value terms in 2006-07.

“With growing longevity, osteoporosis, a condition characterised by loss of bone mass, would gain increased attention.”

Ranbaxy Laboratories Ltd. has a number of new products in its pipeline including Bonista, for the osteoporosis patients who are normally treated by orthopaedics and gynaecologists.

Launched in collaboration with Virchow Biotech Pvt Ltd, which is based in Hyderabad, Bonista is a quality bio-generic therapeutic option to doctors, he said.

An estimated 61 million people in India are reported affected by osteoporosis.

Although data on the prevalence of osteoporotic fractures is limited, it is estimated that each year, osteoporosis causes more than 1.5 million fractures, resulting in permanent disability, loss of independence and death.

Related Stories

Tags: , , , , , , , , , , , , ,

Posted in Health Science |